Showing posts with label Hematology. Show all posts
Showing posts with label Hematology. Show all posts

04 May 2009

Structure and Function of Erythropoietic Tissue



Structure and Function of Erythropoietic Tissue
Presentation lecture from:California State University

The RBCs

Erythropoiesis (RBC production)
* Mature erythrocytes are derived from committed erythroid proginator cells through a series of mitotic divisions and maturation phases.
* Erythropoietin, a humoral agent produced

mainly by the kidneys stimulates erythropoiesis by acting on committed stem cells to induce proliferation and differentiation of erythrocytes in the bone marrow.

o Tissue hypoxia (lack of oxygen) is the main stimulus for erythropoietin production.
o Nucleated red cell precursors in the bone marrow are collectively called normoblasts or erythroblasts.
o RBCs that have matured to the non-nucleated stage gain entry to the peripheral blood.
o Once the cells have lost their nuclei, they are called erythrocytes.

o Young erythrocytes that contain residual RNA are called reticulocytes.
o Bone marrow normoblast proliferation and maturation occurs in an orderly and well defined sequence.
+ The process involves a gradual decrease in cell size, condensation and eventual expulsion of the nucleus, and an increase in hemoglobin production.

Basic blood cell maturation

* Nearly all hematopoietic cells mature in the manner shown below. For RBCs the nucleus is eventually extruded and the cytoplasm increase correlates with hemoglobin increase.
o For red cell production to be efficient , 85% or more of the erythroid activity must have a balanced incorporation of heme and globin to form hemoglobin.
+ The immature, nucleated RBC must have an adequate supply of iron‚ as well as normal production of porphyrin and globin polypeptide chains‚ for adequate synthesis of hemoglobin.
+ Folic acid and vitamin B12‚ are also needed in adequate amounts to maintain proliferation and differentiation.
+ Defects may occur at any stage of development and these defects will lead to the death of the cell.

# Normally 1-15% of the RBCs die during maturation.
# Ineffective erythropoiesis occurs when there is a failure to deliver the appropriate number of erythrocytes to the peripheral blood.
o Normoblasts normally spend 4-7 days proliferating and maturing in the bone marrow.
o The stages of maturation from the most immature to the most mature are:

Pronormoblast or rubriblast
Basophilic normoblast or prorubicyte
Polychromatophilic normoblast or rubicyte
Orthochromic normoblast or metarubicyte
Reticulocyte or polychromatophilic erythrocyte
Mature erythrocyte

+ Reticulocytes are released from the bone marrow into the peripheral blood where they mature into erythrocytes , usually within 24 hours.
+ It is rare to see more than 1% reticulocytes in the peripheral smear from an adult , but common in healthy newborns.
# They can be visualized more easily by staining with new methylene blue which allows for visualization of the remnants of the ribosomes on the endoplasmic reticulum.
o Mature RBCs have a lifespan of 100-120 days and senescent RBCs are removed by the spleen.
o 3 areas of RBC structure/metabolism are crucial for normal erythrocyte maturation, survival and function:
+ The RBC membrane
+ Hemoglobin structure and function
+ Cellular energetics

# Defects or problems associated with any of these will result in impaired RBC survival.
# The RBC must be flexible in order to squeeze through the capillaries of the spleen.
* Flexibility is a property of the membrane and the fluidity of the cell’s content.
# Any decrease in flexibility results in a decrease in RBC deformability and a decrease in RBC survival in passage through the spleen.

The RBC membrane
* The RBC membrane is a semi-permeable lipid bilayer supported by a protein cytoskeleton (contains both integral and peripheral proteins).
* Since the mature cells lack enzymes and cellular organelles necessary to synthesize new lipid or protein, extensive damage cannot be repaired and the cell will be culled in the spleen.

* The constituents of the RBC membrane include:
o Phospholipids- exchange between phospholipids in the membrane and the plasma may occur.
+ Since the fatty acid content of the diet and the plasma are correlated, changes in the diet may have an effect on the fatty acid composition of the phospholipids in the RBC membrane which can adversely effect the flexibility of the RBC and may result in an RBC with a decreased survival time.
o Cholesterol- membrane cholesterol exists in free equilibrium with plasma cholesterol.
+ Therefore, an increase in free plasma cholesterol results in an accumulation of cholesterol in the RBC membrane.
# RBCs with increased cholesterol appear distorted and the increased cholesterol results in the formation of target cells, and acanthocytes.
# An increase in the cholesterol to phospholipid ratio results in a cell membrane that is less deformable and therefore, the RBC has a decreased survival time.

Acanthocytes
Target cells
The RBC membrane
RBC membrane structure
Hemoglobin Structure and Function

* Hemoglobin occupies 33% of the RBC volume and 90-95% of the dry weight.
o 65% of the hemoglobin synthesis occurs in the nucleated stages of RBC maturation and 35% during the reticulocyte stage.
o Normal hemoglobin consists of 4 heme groups, which contain a protoporphyrin ring plus iron, and globin, which is a tetramer of 2 pairs of polypeptide chains.
Structure of hemoglobin
Hemoglobin Structure and Function
Summary of hemoglobin synthesis
Structure of heme
Assembly of hemoglobin
How iron levels affect heme synthesis
Siderocyte
Ringed sideroblast
Hemoglobin Structure and Function
Oxy versus deoxy hemoglobin
Right shift in O2 dissociation curve
Left shift in O2 dissociation curve
Comparison of an O2 dissociation curve at normal pH and with acidosis or alkalosis
Cellular Energetics
Heinz bodies (new methylene blue stain)
Erythrocyte kinetics
Erythrocyte destruction
Extravascular destruction of RBCs
Intravascular destruction of RBCs

Structure and Function of Erythropoietic Tissue.ppt

Read more...

Erythropoiesis Simulating Agents



Erythropoiesis Simulating Agents: New Ideas and Barriers to Drug Development
Presentation lecture by:Jeffrey R. Kanofsky, Loyola University

Objectives

* Physiology of erythropoietin
* Available Epoetins and how they differ
* Untoward Effects
o Thrombotic Complications
o Decreased Survival in Patients with Cancer
* New Agents
o Follow-on Epoetins
+ Regulatory Issues
o Modified Epoetins
o Erythropoietin-receptor agonists with no structural analogies to epoetins
o ESA agents that work by mechanisms other than direct binding to the erythropoietin receptor
* Conclusions

Physiology

* Erythropoietin cell surface receptor
o Member of Type I cytokine receptor family
o Glycoprotein with 484 amino acids and one N-linked glycan (60 kDa)
o Activate cytoplasmic protein tyrosine kinase JAK2
o Receptor is a dimer
+ Erythropoietin binding changes the conformation of the dimer

* Non-hematopoietic function of erythropoietin
o EPO receptors present on many other types of cells including brain, nerves, placenta and endothelial cells
+ The density of receptors appears to be considerably lower than on erythroid precursors
o EPO appears to be important for angiogenesis
o EPO receptors appear to be present on some cancers
+ The specificity of the assay for the EPO receptors has been questioned
* Most erythropoietin produced by interstitial cells of the kidney
o Low oxygen induced EPO gene expansion
+ Transcription activation
+ mRNA stabilization
o Hypoxia inducible factor-1 activation
+ Binds to hypoxia responsive element in the 3’ flanking region of the EPO gene
+ Forms a complex with p300 protein and hepatic nuclear factor 4
o Upstream kidney inducible elements needed for increased renal expression
Oxygen dependent hydroxylation of asparagine residue 803 also blocks binding to p300

Oxygen Mechanism Responsible for Oxygen-Dependent Degradation of HIF-

Hydroxylases
Available Agents
Epoetins
Modified Epoetins
Epoetins

* All have same 165 amino-acid sequence as natural human erythropoietin
* Identical protein tertiary structure not certain
* Different Epoetins differ somewhat in carbohydrates
* Carbohydrate needed for protein stability
o Unconjugated peptide chain has a very short life in circulation
* Epoetin alfa (Procrit, Epogen, Eprex outside the USA)
o Made in Chinese hamster ovary cells
o About 40% carbohydrate, similar to, but not identical to natural erythropoietin
+ Molecular weight about 30 kDa
o Half-life about 7 to 8 hours
* Epoetin beta (NeoRecormon, available in Europe)
o Same 165 amino acid sequence as epoetin alfa and natural erythropoietin
o Made in Chinese hamster ovary cells
o Carbohydrate composition differs somewhat from epoetin alfa
+ A greater proportion of more basic isoforms
o Terminal half-life is 20% longer than epoetin alfa
* Epoetin delta
o Made in human fibrosarcoma cell cultures (HT-1080)
o EPO gene activated by transformation of cells with cytomegalovirus promoter
o Does not have N-glycolyneuramic acid (humans are unable to synthesize this compound)
o Approved by European Agency for the Evaluation of Medicinal Agents (EMEA) in 2002 and marketed in some European countries
* Epoetin omega
o Made in baby hamster kidney cell cultures
o Clinically used in some Eastern European, Central American and Asian countries
Modified Epoetins
* Darbepoetin alfa (Aranesp)
Untoward Effects
* Background
o Epoetins developed in mid to late 1980s
o Risk of HIV infection from a transfusion on the order of 1:2,000
o Current risk 1:1,000,000
o Substantial reductions in risk for transmission for other viral diseases, such as hepatitis C

Effect of Epoetins on Thrombosis and Survival in Cancer Patients
Black Box Warning
* Cancer
Likely New Warnings
Follow-on Epoetins
Regulatory Issues
History of Legal Regulation
Justification for Differences in Regulation
Pure Red Cell Aplasia
* Clinical Features
Follow-On Epoetins
Drug Price Competition and Patent Restoration Act of 1984
(Hatch-Waxman Act)
* Requirements
Standards for Follow-on Biologics in Europe
Working Group on Follow-On Proteins at the FDA
Pathway for Biosimilars Act
New Agents: Modified Epoetins
Continuous Erythropoietin Receptor Activator
Promising Agents not yet in Clinical Trials
GATA Inhibitors
Hemopoietic Cell Phosphatase Inhibitors (SHP-1)
Synthetic Erythropoiesis Protein
Non-Peptide Erythropoietin Mimetics
Conclusions

Erythropoiesis Simulating Agents.ppt

Read more...

26 April 2009

Hyperaemia & Congestion



Hyperaemia & Congestion

Presentation contains:
Hyperaemia
Congestion
Physiological
Pathological
Congestion

* Congestion of capillary beds closely related to the development of oedema (congestion & oedema commonly occour together).
* Chronic passive congestion leads to hypoxia due to stasis of poorly oxygenated blood, resulting in parenchymal cell degeneration or death.
* Capillary rupture at sites of chronic congestion may cause small foci of haemorrhage.
* Breakdown & phagocytosis of red cell debris can result in small clusters of haemosiderin-laden macrophages.
Local Passive Venous Congestion:
Pathological Effects of Congestion
Pathological Effects of Congestion
Chronic Passive Venous Congestion of Spleen

Hyperaemia & Congestion.ppt

Read more...

The Haematopoietic & Lymphoid Systems



The Haematopoietic & Lymphoid Systems

Erythrocytes

* Haematocrit
* MCV - size of RBC
* MCH - Hb content
* MCHC - Hb content
* Anaemia - decreased RBC’s/Hb conc.
* Anisocytosis - variation in size
* Poikilocytosis - abnormal shape
* Polycythemia - increased RBC’s

Leukocytes

* Granulocytes - neutrophil; basophil; eosinophil
* Agranulocytes - lymphocytes; monocytes
* Leukocytosis - increased WBC’s
* Neutrophilia
* Monocytosis
* Eosinophilia
* Basophilia
* Lymphocytosis
* Leukopaenia - decresed WBC’s
* Neutropaenia
* Pancytopaenia
* lymphoaenia


Platelets

* Thrombocytopaenia
* Decreased platelets
* Thrombocytosis
* Increased platelets

Haemopoiesis

* Sites of Haemopoiesis
* Haemopoietic stem cells
* Erythropoiesis
* Leukopoiesis
* Megakaryocytopoiesis
* Blood cells kinetics
* Control of haemopoiesis
* Haemoglobin


Blood Cell Differentiation from Stem Cell

Haemopoiesis
Haemoglobin
Anaemia
Classification of Anaemia
RBC morphology

Haemorrhage & Blood Loss Anaemia
Iron-deficiency Anaemia
Mechanisms of Iron Deficiency
Iron Metabolism
Clinical Pathogenesis
Clinical Morphology & Features
Diagnostic Criteria
Megaloblastic Anaemia
Megaloblast

Fe accumulation in bone marrow
Affects granulocyte & platelet precursors
Pancytopaenia
Morphology
Vitamin B12 Deficiency Anaemia
Mechanisms of Deficiency
Vit B12
Folate Deficiency Anaemia
Anaemia of Chronic Disorders
Chronic inflam disease
Aplastic (hypoplastic) Anaemia
Aetiology
Pathogenesis
Myelopthisic Anaemia
Haemolytic Anaemia
Consequences of Haemolytic Anaemia
Immune Haemolyitic Anaemias
Hereditary Spherocytosis
Sickle Cell Anaemia
Haemoglobinopathy
Factors that influence sickling
Hereditary spherocytosis
Thalassemia
β-thalassemia
Thalassemia major
Thalassemia minor
Glucose-6-Phosphate Dehydrogenase Deficiency
Pyruvate Kinase Deficiency
Paroxysmal Nocturnal Haemoglobinuria
Immunohaemolytic Anaemias
Warm Ab Immunohaemolytic Anaemia
Cold Ab Immunohaemolytic Anaemia
Microngiopathic Haemolytic Anaemia
Malaria
Leukaemia
Acute Leukaemia
Chronic Leukaemia
Clinical Course
Chronic Lymphocytic Leukaemia (CLL)
Chronic Myeloid Leukaemia (CML)
Myelodysplastic Disorders
Myeloproliferative Disorders
Natural History of Myeloproliferative Disorders
Polycythaemia rubra vera
Common aetiological conditions & pathology
Myelofibrosis
Essential Thrombocythaemia
Plasma Cell Dyscrasias
Multiple Myeloma
Pathology of Bone Disease in MM
Disorders of Primary Haemostasis
Thrombocytopaenia (decreased platelets in blood due to excessive destruction or decreased production)
Idiopathic Thrombocytopaenic Purpura
Thrombotic Microangiopathies (disorders of small vessels resulting in thrombosis)
Thrombocytic Thrombocytopaenic Purpura
Fundamental to TTP & HUS
Immune Thrombocytopaenias
Acquired Disorders of Platelet Function
Bleeding Due to Vascular Disorders
Henoch-Schonlein Purpura
Disorders of Blood Coagulation
Haemophilia (inherited disorder in which the blood clots very slowly due to deficiency of clotting factors)
Von Willebrand Disease
Disseminated Intravascular Disease
Aetiological factors
Haemorrhage & ischaemia

The Haematopoietic & Lymphoid Systems.ppt

Read more...

24 April 2009

Hemostasis / Thrombosis



Hemostasis / Thrombosis II

Congenital/Acquired Hemorrhagic Disorders & Their Treatment

COAGULATION TESTING
PLATELET FUNCTION DEFECTS
Prolonged Bleeding Time
PLATELET FUNCTION DEFECTS
Platelet Adhesion
Acquired - Drug Induced
Platelet Function Disorders
Treatment
THROMBOCYTOPENIA
Increased Destruction - Causes
IDIOPATHIC THROMBOCYTOPENIA PURPURA
HIV-ASSOCIATED THROMBOCYTOPENIA
CONGENITAL CLOTTING DISORDERS
COAGULATION TESTING
Clotting Factor Deficiency
Determination of missing factor
VON WILLEBRAND DISEASE
VON WILLEBRAND FACTOR
Diagnostic Studies
Classification
Treatment
HEMOPHILIA
Clinical Severity - Correlates with Factor Level
Platelet Activation
HEMOPHILIA vs. VON WILLEBRAND DISEASE

HEMOPHILIA – General Rules
Initial Therapy of Hemophilia A
Initial Therapy of Hemophilia B
HEMOPHILIA Rx
Subsequent Treatment
Factor Concentrates
FACTOR XI DEFICIENCY
Other coagulation factor disorders
Clotting Factor Deficiency Treatment
CLOTTING DISORDERS
VITAMIN K DEFICIENCY
Acquired
LIVER DISEASE


HEMOSTASIS / THROMBOSIS II.ppt

Read more...

23 April 2009

Hematology Laboratory Instructional Videos



Hematology Laboratory Instructional Videos from University of Virginia

Standard Venipuncture Procedure
Click to view or Right click and save as to download


Butterfly Procedure
Click to view or Right click and save as to download


How to Prepare a Blood Smear
Click to view or Right click and save as to download


Automated CBC: What really happens in the lab
Click to view or Right click and save as to download

Read more...

22 April 2009

RBC Disorders



RBC Disorders
Presentation by: Joyce Smith RN, BSN

* Decreased Production of RBC
* Iron Deficiency Anemia
* Vitamin B12 Deficiency Anemia
* Folic Acid Deficiency Anemia
* Aplastic Anemia

Fe Deficiency Anemia
* Common world wide
* Affects 10-30% of population in US
* Common in premenapausal woman, infants, children, adolescents, & elderly
* Develops slowly

A&P

* Occurs when supply of Fe is too low for optimal RBC formation
* Iron RDA
* 10mg/d M,
* F 12-49 15 mg
* Typical American diet provides 10 to 20 mg/d
* Many woman consume only 12.4mg/d

Cause of Development

* Inadequate absorption or excess Fe loss
* Inadequate dietary intake of foods high in Fe
* Principal cause in adults acute or chronic bleeding
* Secondary to trauma
* Excessive menses
* GI bleeding
* Blood donation

Diagnostics

* Hgb Panic value < 5g/dl
* Hgb level can drop to 3.6g/dl
* Total RBC count rarely below 3 million/dl
* MCH < 27 pg
* MCHC 20 to 30 g/dl
* Serum Fe as low as 10mcg./dl
* HCT < 47 ml/dl M
* HCT < 42 ml/dl F
* Fe binding capacity 
* Serum ferritin level 
* Bone marrow may also be indicated

Symptoms

* Pallor, glossitis
* Dizziness, irritability, numbness & tingling in limbs, fatigue, decreased concentrated & HA
* Tachycardia & dyspnea on exertion
* Sensitivity to cold, brittle hair & nails
* Atrophic glossitis, stomatitis, dysphagia

Treatment
Nursing Care
Folic Acid Deficiency
Food Sources
Clinical Manifestations
Treatment
Aplastic Anemia
Clinical manifestations
Treatment of Aplastic Anemia
Treatment
RBC Disorders
Polycythemia
Clinical Manifestations
Diagnostic Tests
Management

Hematology.ppt

Read more...

Hematology



Hematology
By: Joyce Smith RN BSN
Introduction

* Red Blood Cell Disorders
* White Blood Cell Disorders
* Coagulation Disorders
* Clotting Factor Disorders

RBC Destruction
Sickle Cell Disease
Sickle Cell Crisis
Diagnostic Tests
Clinical Manifestations
Health History
Assess
General Management
Drug Therapy
Immunohemolytic Anemia
or Autoimmune Hemolytic Anemia
Immunohemolytic Anemia
or Autoimmune Hemolytic Anemia
Treatment
Vitamin B 12 Deficiency
Diagnostic Tests
Treatment
Folic Acid Deficiency
Food Sources
Clinical Manifestations
Treatment

Hematology.ppt

Read more...

Hematological System



Hematological System
Presentation by:Joyce Smith RN BSN

Functions of Blood
Bone Marrow
Blood Components
Spleen
Lymph System
Liver
Normal Clotting Mechanism
Gerontological Considerations
Anticoagulants
Thrombolytic
Key Symptoms
Health History
Physical Assessment
Skin
Head & Neck
Respiratory
Cardiovascular
Renal & Urinary
Musculoskeletal
CNS
Psychosocial
Complete Blood Count (CBC)
Reticulocyte Count
Hemoglobin Electrophoresis
Coombs’ Test
Serum Ferritin
Bleeding Time
Prothrombin Time
International Normalized Ratio
Partial Thromboplastin Time
Bone Marrow Aspiration
Nursing Responsibilities

Hematological System.ppt

Read more...

19 April 2009

Newer Anticoagulant Therapies



Newer Anticoagulant Therapies
Presentation by:Chris Ferrell MT(ASCP), CLS/H(NCA)

Special Coagulation Lead
Harborview Medical Center
University of Washington

Heparin Therapy
Lupus Anticoagulant and PTT
Monitoring Heparin Therapy in Patients with LA
Warfarin Therapy
Lupus Anticoagulant and Protime
Monitoring Coumadin Therapy in Patients with LA
Low Molecular Weight Heparin
Antithrombin
Thrombin
Unfractionated Heparin
Pentasaccharide
Antithrombin
Factor Xa
Pentasaccharide
LMWH Comparisons
Tinzaparin
Reviparin
Nadroparin
Enoxaparin
Dalteparin
Ardeparin
Advantages
FDA Approved Indications of LMWHs
Total knee replacement
Total hip replacement
General surgery
LMWH Administration
PTT and LWMH
LMWH Comparisons
Low Molecular Weight Heparin
Other Tests to Monitor Heparin
Problems with Monitoring Heparin Therapy with PTT’s
Why Use LMWH vs. UFH?
Heparin Induced Thrombocytopenia
What Is It?
Heparin Induced Thrombocytopenia
HIT Testing
How Do You Diagnose It?
HIT Testing by Aggregometry
Light source
Positive HIT Test
Patient Plasma
Heparin Induced Thrombocytopenia
Advances in Anticoagulation
Direct Thrombin Inhibitors
Hirudin and Derivatives
Thrombin and Hirudin
Direct Thrombin Inhibitors
Hirudin and Derivatives
Direct Thrombin Inhibitors Hirudin and Derivatives
Direct Thrombin Inhibitors
Clinical Trials of Direct Thrombin Inhibitors
Direct Thrombin Inhibitors
Effect on Laboratory Testing
Low Molecular Weight Heparin
Fondaparinux
Inhibition of VIIa/TF
Tissue Factor Pathway Inhibitor
Enhanced Protein C Pathway
Enhancement of the fibrinolysis
Advances in Anticoagulation
Platelet Function Inhibitors
Ideal Anticoagulant

Newer Anticoagulant Therapies,ppt

Read more...

15 April 2009

Hematology



Hematology
Presentation By
Joyce Smith RN BSN

Topics covered:
Introduction

* Red Blood Cell Disorders
* White Blood Cell Disorders
* Coagulation Disorders
* Clotting Factor Disorders

RBC Destruction: Sickle Cell Disease
Sickle Cell Disease
Sickle Cell Crisis
Diagnostic Tests
Clinical Manifestations
Health History
Assess
General Management
Drug Therapy
Immunohemolytic Anemia
or Autoimmune Hemolytic Anemia
Immunohemolytic Anemia
or Autoimmune Hemolytic Anemia
PERNICIOUS ANEMIA or Vitamin B 12 Deficiency
A & P
Symptoms
Diagnostic Tests
Treatment
Folic Acid Deficiency
Food Sources
Clinical Manifestations
Treatment

Hematology.ppt

Read more...

Hematology Emergencies



Hematology Emergencies
Presentation by Jack Lazerson, M.D.
Professor Emeritus
Department of Pediatrics
University of Nevada School of Medicine

Clinical emergencies: diagnosis and treatment
1. Clinical history including family history
2. Physical examination
3. Minimum laboratory evaluation

Common Disorders and Treatment

1. I.T.P.
2. Thrombocytopenia (non immune)
3. Thrombopathies
4. von Willebrand’s Disease
5. Coagulation Factor Deficiencies
6. Thrombosis


Thrombosis
Mechanism of Inhibitors:
Laboratory Assays:
Treatment
Advances in Blood Component Therapy

------------
Jack Lazerson, M.D.
Professor Emeritus
Department of Pediatrics
University of Nevada School of Medicine

Anemia

Red Blood Cell Transfusions
Erythropoietin
Stimulates
Minimum laboratory evaluation
Platelet Transfusions
Thrombocytopenia (non-immune)
Blood Coagulation Factors
von Willebrand’s Disorder
Apheresis

Hematology Emergencies

Read more...

Cancer Education Slides



Cancer Education Slides
from cancer.net

Chronic Lymphocytic Leukemia
What is Cancer?
What is Chronic Lymphocytic Leukemia (CLL)
What is the Function of Lymphocytes
What are the Types of CLL
What are the Risk Factors for CLL
What are the Symptoms of CLL
How is CLL Diagnosed
CLL Staging
Stage 0 CLL
Stage I CLL
Stage II CLL
Stage III CLL
Stage IV CLL
Risk Groups of CLL

European Staging System (Binet Classification)
How is CLL Treated?

* Treatment depends on the patient’s stage, risk status and overall health
* Watch and wait option: many people may not require treatment right away
* Chemotherapy
* Biologic therapy
* Radiation therapy
* More than one treatment may be used
* Use of drugs to kill cancer cells

CLL Treatment: Biologic Therapy
CLL Treatment: Radiation Therapy
Supportive Treatment for CLL
Current Research: Stem Cell Transplantation
Current Research: Other Areas
The Role of Clinical Trials for the Treatment of CLL
Clinical Trials: Patient Safety
Clinical Trials: Phases
Clinical Trials Resources
Coping with Side Effects

More Information

Read more...

White Blood Cell Disorders



White Blood Cell Disorders
Presentation by: Jonathan Ben-Ezra, M.D.
Professor of Pathology
MCV Campus of VCU

Topics covered

White Blood Cells
Granulocytes
Lymphocytes
Leukemia
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Myelofibrosis
Chronic Lymphocytic Leukemia
Multiple Myeloma
Infectious Mononucleosis
Lymphomas
Diffuse vs. Follicular Lymphoma
Low grade NHL
Small Lymphocytic Lymphoma
Follicular Lymphoma
High Grade NHL
Large Cell Lymphoma
Burkitt’s Lymphoma
Burkitt’s Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT)
Hodgkin Lymphoma

White Blood Cell Disorders

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP